On January 2, Gelonghui reported that HEPALINK (09989.HK) announced that the company signed a distribution agreement with Zhejiang Yongtai Pharmaceutical Co., Ltd. ("Yongtai Pharmaceutical") on December 31, 2024, under which Yongtai Pharmaceutical grants the company the license to commercialize Gabapentin capsules ("symbol") throughout the USA.
According to the agreement, the company will purchase the symbol from Yongtai Pharmaceutical at an agreed price and will be responsible for the commercialization of the symbol in the USA. Apart from the supply price of the symbol expressly stipulated in the agreement, the company is not required to pay any additional fees to Yongtai Pharmaceutical.